These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 6114853

  • 21. Thyroid stimulating immunoglobulin in Graves' disease.
    Luttrell BM, Hales IB.
    Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
    [Abstract] [Full Text] [Related]

  • 22. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
    Bech K.
    Acta Endocrinol Suppl (Copenh); 1983 Jun; 254():3-38. PubMed ID: 6191508
    [No Abstract] [Full Text] [Related]

  • 23. Discrepancy between thyroid-stimulating and thyrotropin-binding inhibitory activities of Graves' immunoglobulin Gs assessed in the mouse.
    Shishiba Y, Ozawa Y, Ohtsuki N, Shimizu T.
    J Clin Endocrinol Metab; 1982 Apr; 54(4):858-62. PubMed ID: 6277983
    [Abstract] [Full Text] [Related]

  • 24. Interaction between thyroid-stimulating immunoglobulins and thyrotropin receptors in fat cell membranes.
    Kishihara M, Nakao Y, Baba Y, Matsukura S, Kuma K, Fujita T.
    J Clin Endocrinol Metab; 1979 Nov; 49(5):706-11. PubMed ID: 226558
    [Abstract] [Full Text] [Related]

  • 25. The effects of synthetic alpha-subunit peptides on thyroid-stimulating immunoglobulin activity.
    Morris JC, Jiang NS, Hay ID, Charlesworth MC, McCormick DJ, Ryan RJ.
    J Clin Endocrinol Metab; 1988 Oct; 67(4):707-12. PubMed ID: 2458377
    [Abstract] [Full Text] [Related]

  • 26. Serum protein inhibition of thyrotropin binding to human thyroid tissue.
    Beall GN, Chopra IJ, Solomon DH, Kruger SR.
    J Clin Endocrinol Metab; 1978 Nov; 47(5):967-73. PubMed ID: 45474
    [Abstract] [Full Text] [Related]

  • 27. Graves' disease: thyroid function and immunologic activity.
    Gossage AA, Crawley JC, Copping S, Hinge D, Himsworth RL.
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [Abstract] [Full Text] [Related]

  • 28. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H, Kuwert T, Lohmann T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [Abstract] [Full Text] [Related]

  • 29. The adenylate cyclase-cyclic AMP system in Graves' disease.
    Field JB, Muto H, Chou MC.
    Adv Cyclic Nucleotide Res; 1980 Apr; 12():359-72. PubMed ID: 6250367
    [No Abstract] [Full Text] [Related]

  • 30. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P, Chiovato L, Fiore E, Mammoli C, Rocchi R, Pinchera A.
    Acta Med Austriaca; 1996 Apr; 23(1-2):52-6. PubMed ID: 8767515
    [Abstract] [Full Text] [Related]

  • 31. The effect of sialic acid on adenylate cyclase activity and thyrotropin-receptor binding in human thyroid membranes.
    Adler GM.
    Acta Biochim Pol; 1978 Apr; 25(4):343-7. PubMed ID: 220831
    [Abstract] [Full Text] [Related]

  • 32. [Radioreceptor assay of TSH].
    Torizuka K, Konishi J, Endo K, Ikekubo K, Mori T.
    Nihon Rinsho; 1976 Apr; 34(3):471-6. PubMed ID: 778435
    [No Abstract] [Full Text] [Related]

  • 33. Thyrotropin binding and long acting thyroid stimulator absorbing activities in subcellular fractions from isolated thyroid cells and thyroid homogenates.
    Mehdi SQ, Badger J, Kriss JP.
    Endocrinology; 1977 Jul; 101(1):59-65. PubMed ID: 193685
    [Abstract] [Full Text] [Related]

  • 34. Thyrotropin binding and adenylate cyclase activation in normal and neoplastic human thyroid tissue: lack of effect of thyroglobulin.
    Clark OH, Gerend PL, Nissenson RA.
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1157-63. PubMed ID: 7076796
    [Abstract] [Full Text] [Related]

  • 35. TSH and thyroid stimulating antibodies (TSAb) activate thyroid adenylate cyclase through different pathways.
    Madsen SN, Bech K.
    Acta Med Scand Suppl; 1979 Jun; 624():35-42. PubMed ID: 284712
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of TBII activity in untreated Graves' disease using solubilised thyroid membranes.
    Taylor JJ, Young ET, Holcombe M, Kendall-Taylor P.
    Ann Clin Biochem; 1985 Jul; 22 ( Pt 4)():366-70. PubMed ID: 2864013
    [Abstract] [Full Text] [Related]

  • 37. The use of proteolytic enzyme inhibitor (Trasylol) in radioreceptor assay of TSH-its application to measuring thyroid stimulating immunoglobulins (TSI) in thyroid diseases.
    Kishihara M, Nakao Y, Baba Y, Ohgo S, Matsukura S, Kuma K, Imura H.
    Acta Endocrinol (Copenh); 1978 May; 88(1):65-74. PubMed ID: 77120
    [Abstract] [Full Text] [Related]

  • 38. [Loss of high-affinity prostacyclin binding sites in patients with Basedow's disease].
    Virgolini I, Weiss K, Hermann M, Sinzinger H, Höfer R.
    Nuklearmedizin; 1989 Feb; 28(1):17-20. PubMed ID: 2540480
    [Abstract] [Full Text] [Related]

  • 39. Heterogeneous signal pathways through TSH receptors in porcine thyroid cells following stimulation with Graves' immunoglobulin G.
    Szabó J, Fóris G, Keresztes T, Csabina S, Varga Z, Bakó G, Mezõsi E, Nagy E, Paragh G, Leövey A.
    Eur J Endocrinol; 1998 Sep; 139(3):355-8. PubMed ID: 9758449
    [Abstract] [Full Text] [Related]

  • 40. Evidence for normal thyroidal adenyl cyclase, cyclic AMP-binding and protein-kinase activities in Graves' disease.
    Orgiazzi J, Chopra IJ, Williams DE, Solomon DH.
    J Clin Endocrinol Metab; 1975 Feb; 40(2):248-55. PubMed ID: 165418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.